A Study of HS-10518 in Healthy Female Participants - Trial NCT06118827
Access comprehensive clinical trial information for NCT06118827 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Endometriosis. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Nov 01, 2023
Aug 30, 2024
Primary Outcome
Incidence of Adverse Events (AE) as assessed by CTCAE v4.0,Assessment of safety and tolerability of HS-10518 in terms of the frequency, severity and causality of AEs, serious adverse events (SAEs) and AEs leading to study discontinuation.,Incidence of clinically significant abnormal findings in 12-lead electrocardiogram (ECG)
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
 pharmacodynamics of HS-10518 in healthy adult premenopausal females in China.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06118827
Non-Device Trial